Acipimox

DRUG18 trials

Conditions

Abdominal ObesityAcute Heart FailureBrain DiseasesBulimia NervosaCardiomyopathy, DilatedCardiovascular DiseasesDiabetesDiabetes Mellitus Type 2

Phase 1

Free Fatty Acids and Vascular Function in Subjects With Diabetes

CompletedNCT00153179

Brigham and Women's HospitalType 2 Diabetes Mellitus

Start: 2005-09-30End: 2013-03-31Updated: 2018-09-25

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

CompletedNCT02256722

Boehringer IngelheimHealthy

Start: 2005-10-31Updated: 2014-10-06

Phase 2

Metabolic Modulation as Treatment in Acute Heart Failure

TerminatedNCT00449423

University of AarhusAcute Heart Failure

Start: 2007-03-31End: 2007-10-31Target: 32Updated: 2007-10-25

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

CompletedNCT00759291

Brigham and Women's HospitalMetabolic Syndrome

Start: 2006-04-01End: 2017-12-30Updated: 2023-02-21

Effects of Acipimox on Mitochondrial Function in Obesity

CompletedNCT01488409

Massachusetts General HospitalAbdominal Obesity, Hypertriglyceridemia, Insulin Resistance

Start: 2012-05-31End: 2015-01-31Updated: 2016-03-01

The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes

CompletedNCT01980524

Medical University of ViennaType 2 Diabetes

Start: 2013-10-31End: 2016-05-31Updated: 2017-04-04

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

Enrolling by invitationNCT03338387

Charles University, Czech RepublicBulimia Nervosa, Eating Disorder

Start: 2003-05-06End: 2026-12-20Target: 24Updated: 2025-02-19

Phase 3

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

CompletedNCT01816165

University of Colorado, DenverType 1 Diabetes

Start: 2011-06-30End: 2015-06-24Updated: 2022-01-21

Unknown Phase

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

CompletedNCT00246402

National Heart, Lung, and Blood Institute (NHLBI)Cardiovascular Diseases, Heart Diseases, HIV Infections +3

Start: 2002-09-30End: 2006-08-31Target: 30Updated: 2014-05-15

Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

CompletedNCT00549614

University of AarhusHeart Failure

Start: 2007-10-31End: 2009-05-31Target: 28Updated: 2009-10-07

Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function

CompletedNCT00943059

Maastricht University Medical CenterCardiomyopathy, Dilated, Diabetes Mellitus, Type 2

Start: 2010-03-31End: 2012-12-31Updated: 2013-05-14

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

CompletedNCT01209416

University of AarhusHypopituitarism, Insulin Resistance, Metabolism

Start: 2012-06-30End: 2015-10-31Target: 8Updated: 2017-10-30

Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise

CompletedNCT01260376

University of AarhusDiabetes, Obesity

Start: 2011-04-30End: 2012-09-30Updated: 2012-09-18

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

CompletedNCT01580813

University of Colorado, DenverType 2 Diabetes

Start: 2011-06-30End: 2015-06-05Updated: 2021-12-03

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

CompletedNCT02782208

University of AarhusBrain Diseases, Endocrine System Diseases, Glucose Metabolism Disorders +4

Start: 2016-02-10End: 2016-12-22Updated: 2020-03-26

Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men

CompletedNCT02792621

Royal Devon and Exeter NHS Foundation TrustImpaired Mitochondrial Function, Muscle Performance

Start: 2016-11-08End: 2019-12-15Updated: 2020-03-10

The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

CompletedNCT02796950

University of AarhusDiabetes Mellitus Type 2

Start: 2016-06-30End: 2017-01-20Updated: 2018-05-08

Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance

TerminatedNCT03325491

University of ExeterImpaired Mitochondrial Function, Muscle Performance

Start: 2018-03-07End: 2019-09-16Updated: 2019-09-27

Endocrinology Diabetes & Metabolism2025-01-312 citations

Abstract 17927: Acipimox Does Not Improve Endothelial Function and Insulin-Stimulated Vasodilation in Patients With Metabolic Syndrome

Circulation2023-11-071 citations

Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity

Diabetologia2020-11-3073 citations

Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals.

2020-09-1810 citations

Acipimox Administration With Exercise Induces a Co-feedback Action of the GH, PP, and PYY on Ghrelin Associated With a Reduction of Peripheral Lipolysis in Bulimic and Healthy-Weight Czech Women: A Randomized Study

Frontiers in Endocrinology2019-03-1211 citations

Reduction of non-esterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: a randomised clinical trial.

2013-12-0651 citations